- Home
- VSCO vs IBRX Comparison
VSCO vs IBRX Comparison
Compare VSCO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSCO
- IBRX
- Stock Information
- Founded
- VSCO 1977
- IBRX 2014
- Country
- VSCO United States
- IBRX United States
- Employees
- VSCO N/A
- IBRX N/A
- Industry
- VSCO Clothing/Shoe/Accessory Stores
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSCO Consumer Discretionary
- IBRX Health Care
- Exchange
- VSCO Nasdaq
- IBRX Nasdaq
- Market Cap
- VSCO 2.2B
- IBRX 1.9B
- IPO Year
- VSCO N/A
- IBRX N/A
- Fundamental
- Price
- VSCO $27.96
- IBRX $3.42
- Analyst Decision
- VSCO Hold
- IBRX Strong Buy
- Analyst Count
- VSCO 12
- IBRX 3
- Target Price
- VSCO $40.33
- IBRX $13.58
- AVG Volume (30 Days)
- VSCO 2.0M
- IBRX 6.0M
- Earning Date
- VSCO 03-05-2025
- IBRX 03-18-2025
- Dividend Yield
- VSCO N/A
- IBRX N/A
- EPS Growth
- VSCO 54.91
- IBRX N/A
- EPS
- VSCO 1.95
- IBRX N/A
- Revenue
- VSCO $6,207,000,000.00
- IBRX $7,332,000.00
- Revenue This Year
- VSCO $2.99
- IBRX $2,359.81
- Revenue Next Year
- VSCO $1.74
- IBRX $808.10
- P/E Ratio
- VSCO $14.32
- IBRX N/A
- Revenue Growth
- VSCO 1.42
- IBRX 1218.71
- 52 Week Low
- VSCO $15.12
- IBRX $2.28
- 52 Week High
- VSCO $48.73
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- VSCO 20.67
- IBRX 52.26
- Support Level
- VSCO $31.65
- IBRX $3.35
- Resistance Level
- VSCO $33.22
- IBRX $4.27
- Average True Range (ATR)
- VSCO 1.46
- IBRX 0.31
- MACD
- VSCO -0.40
- IBRX 0.04
- Stochastic Oscillator
- VSCO 3.39
- IBRX 29.17
About VSCO Victorias Secret & Co.
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime. The Company operates as a single segment designed to serve customers worldwide seamlessly through stores and online channels.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.